Fig. 1 · Structure

Documents & Downloads

Enoxolone (Glycyrrhetinic acid)

Cat. No. A10353 CAS 471-53-4

15-PGDH inhibitor

Glycyrrhetinic acid inhibits the enzymes (15-hydroxyprostaglandin dehydrogenase and delta-13-prostaglandin) that metabolize the prostaglandins PGE-2 and PGF-2α to their respective 15-keto-13,14-dihydro metabolites which are inactive.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
15-hydroxyprostaglandin dehydrogenase

Enoxolone (Glycyrrhetinic acid) Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of Enoxolone (Glycyrrhetinic acid) from 1 published reference.

Enoxolone (Glycyrrhetinic acid) In Vitro Studies

In MDCKII cells exposed to pooled rat plasma, glycyrrhetinic acid uptake was similar in mock cells and cells expressing human OAT1 or OAT3. This result limits assumptions about transporter-mediated access of the parent compound under these conditions; it is not an assay of OAT inhibition. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

No enhanced GA uptake in OAT1- or OAT3-expressing cells

Cell-based study · MDCKII cells expressing human OAT1 or OAT3 compared with mock cells [1]

GA uptake was similar in transporter-expressing and mock cells under the tested plasma conditions. This negative transport result does not establish transporter inhibition or exclude uptake in other conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell-associated parent GA after plasma exposureRelative uptake comparison Similar uptake in mock, OAT1 and OAT3 cells; mean ± S.E., n = 6 for cell experiments (Fig. 10D caption).[1]

Literature-Reported Treatment Conditions

Treatment concentration
7.0 µM GA in pooled female EHBR plasma; this plasma also contained 15 µM compound 1
Exposure duration
15 min at 37 °C
Method
Exposure to pooled plasma reconstituted at pH 5.5; comparison with mock cells
Vehicle
Pooled rat plasma, lyophilized and reconstituted in 10 mM MES (pH 5.5)
Co-treatment
Plasma mixture containing endogenous constituents and GA metabolites; not a purified GA-only treatment
Reported limits
n = 6 is reported without specifying independent plasma preparations. No equivalence test or transporter-inhibition endpoint is reported.
Methods and source locations

Compound reported in the paper: 18β-Glycyrrhetinic acid; Compound label in the paper: GA in pooled plasma

Applies to the reported research material; does not establish an Adooq lot, formulation equivalence or clinical efficacy.

Figure 10D and caption; corresponding Results and Methods; Chemicals and reagents

Cell-associated parent GA after plasma exposure: LC-MS/MS of cell extracts, normalized to protein; transporter function checked with p-aminohippurate and estrone sulfate probe substrates. — Figure 10D and caption; Results and Methods: Uptakes of compound 1 by rat kidney slices and cells expressing OAT1 and 3

Enoxolone (Glycyrrhetinic acid) In Vivo Studies

In rats, oral glycyrrhetinic acid (200 mg/kg) produced detectable plasma parent compound within 30 min in both Sprague-Dawley rats and Mrp2-deficient EHBRs. Urinary parent GA was almost undetectable over the 12-h observation period. This pharmacokinetic experiment did not test therapeutic efficacy. [1]

Parent-compound pharmacokinetics in SD rats and EHBRs

Animal study · Female, 9-week-old Sprague-Dawley rats and Eisai hyperbilirubinemia rats (EHBRs; dysfunctional Mrp2) [1]

After oral GA, parent compound appeared in plasma by 30 min and remained detectable over 12 h in both strains. Urinary parent GA was almost undetectable. This was an exposure/metabolite study, without a therapeutic efficacy endpoint.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Parent GA in plasma and urineQualitative exposure profile Plasma appearance at 30 min; sustained over 12 h; urinary elimination almost undetectable (authors’ description). Mean ± S.E., n = 4 in Fig. 9.[1]

Conditions shared by the study groups

Route
Oral
Frequency
Single administration
Treatment course
12-h observation
Vehicle
0.5% CMC
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
SD rats and EHBRs given GA
200 mg/kg
Comparison of two strains receiving the same GA dose, with time-zero sampling; no disease-efficacy comparisonGA detected in plasma by 30 min in both strains; urinary GA almost undetectable over the observation period.[1]
SD rats and EHBRs given GA
Model: Female 9-week-old SD rats and EHBRs; n = 4 as reported in Figure 9 caption
Reported limits: Figure 9 caption does not define whether n represents independent animals versus analytical replicates beyond reporting n = 4.
Methods and source locations

Compound reported in the paper: 18β-Glycyrrhetinic acid; Compound label in the paper: GA

Applies to the reported research material; does not establish an Adooq lot, formulation equivalence or clinical efficacy.

Figure 9B,D and caption; Methods: Chemicals and reagents, Animals, Pharmacokinetic experiments

Parent GA in plasma and urine: LC-ESI(+)-MS/MS; no exact concentrations estimated from plotted curves. — Results: Pharmacokinetic profiles of compound 1 in EHBR treated with GA; Figure 9B,D and caption; Methods: Pharmacokinetic experiments

SD rats and EHBRs given GA · Figure 9B,D and caption; corresponding Results; Methods: Pharmacokinetic experiments of compound 1 in SD rats or EHBRs orally treated with GA

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 471-53-4
Applications 15-PGDH inhibitor
Formula C30H46O4
Molecular Weight 470.7
Synonyms Glycyrrhetin; Uralenic acid; Glycyrrhetinate; Arthrodont; Glycyrrhetinic acid
SMILES
C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)(C)C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 85 mg/mL (180.59 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
2% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Enoxolone (Glycyrrhetinic acid) Research References

  1. [1] Osamu Morinaga, Kan’ichiro Ishiuchi, Takeshi Ohkita, et al. Isolation of a novel glycyrrhizin metabolite as a causal candidate compound for pseudoaldosteronism Scientific Reports (2018). PMID: 30348944 DOI: 10.1038/s41598-018-33834-9 Source material

Added to your cart

View Cart Checkout
Loading...